Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. reports news on its dermatology therapeutics business, including commercialization of YCANTH (VP-102) for molluscum contagiosum and development of cantharidin-based therapy for common warts. Company updates also cover financial results, corporate presentations, commercial leadership and international commercialization activity.
Verrica’s pipeline news centers on VP-315 (ruxotemitide), an oncolytic peptide licensed for dermatologic oncology indications. Recurring disclosures include clinical data presentations in basal cell carcinoma, development plans for non-melanoma skin cancers and collaboration activity tied to YCANTH and its dermatology portfolio.
Verrica Pharmaceuticals (NASDAQ: VRCA) reported Q2 2024 financial results, highlighting $4.9M in YCANTH® revenue. The company expanded YCANTH's distribution through Cencora, Inc. and announced positive Phase 2 results for VP-315 in basal cell carcinoma treatment. Verrica is preparing for a global Phase 3 Common Warts trial, expected to start in 1H 2025. Key financial highlights include:
- Net product revenue: $4.9M
- Collaboration revenue: $0.3M
- Net loss: $17.2M ($0.37 per share)
- Cash and equivalents: $31.9M (as of June 30, 2024)
The company expects continued YCANTH prescription growth in H2 2024, driven by a permanent J-Code and expanded insurance coverage.
Verrica Pharmaceuticals announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, an investigational oncolytic peptide-based immunotherapy for basal cell carcinoma (BCC). Key findings include:
- No treatment-related serious adverse events reported
- Overall 86% reduction in tumor size for all treated lesions
- 51% of lesions achieved complete histological clearance
- Patients with residual tumor achieved an average 71% reduction in tumor size
The company views VP-315 as a potential first-line therapy for BCC, with possible use in primary and neoadjuvant settings. Verrica plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine next steps for VP-315's development.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company, has announced a conference call and webcast scheduled for August 14, 2024, at 8:30 a.m. ET. The event will cover two main topics:
1. The company's financial results for the second quarter ended June 30, 2024.
2. An overview of preliminary topline results from Part 2 of the Phase 2 trial of VP-315 for the treatment of basal cell carcinoma.
Interested parties can join via phone or webcast. The webcast will be archived on Verrica's website for 90 days after the event.
Verrica Pharmaceuticals (Nasdaq: VRCA) announced a settlement with Dormer Laboratories, resulting in Dormer halting sales of cantharidin-containing products in the U.S. Verrica's FDA-approved YCANTH is now the sole commercially available cantharidin therapy for molluscum contagiosum, a skin disease. CEO Ted White emphasized the importance of FDA approval for patient safety and indicated increased market usage for YCANTH as a result. The settlement underscores Verrica's commitment to preventing the distribution of non-FDA approved cantharidin products in the U.S.
Verrica Pharmaceuticals (Nasdaq: VRCA), a company focused on developing dermatology therapeutics, announced that its President and CEO, Ted White, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City.
The event will take place on June 6, 2024, at 3:30 pm ET. A live webcast of the event will be available through the investors' section of the Verrica website, with a replay accessible for 90 days post-event.
Verrica Pharmaceuticals announced an amendment to its collaboration with Torii Pharmaceutical to jointly conduct a global pivotal Phase 3 clinical trial for YCANTH® in treating common warts, expected to start in the first half of 2025. The cost will be equally shared, with Torii funding Verrica's portion through future payment offsets. Verrica highlighted the significant commercial prospects for YCANTH, given the 22 million common wart patients in the U.S. alone and no FDA-approved treatments. Torii will also make an $8 million milestone payment to Verrica upon the first patient dosing in Japan. The trial's initiation depends on feedback from the FDA and Japan's PMDA.
Verrica Pharmaceuticals Inc. reported $3.2M revenue for YCANTH® in Q1 2024. Over 228M lives covered by commercial insurance. Phase 2 results for VP-315 expected in Q2 2024. Conference call scheduled. Key achievements include FDA status, J-Code, and distribution agreements. Financially, $3.2M in product revenue, $0.6M in collaboration revenue. Increased expenses in SG&A and R&D. Net loss of $20.3M.
Verrica Pharmaceuticals Inc. announced that its President and CEO will present at upcoming investor conferences hosted by RBC Capital Markets and HCW BioConnect. The webcasts can be accessed on the company's website for 90 days after the events.
Verrica Pharmaceuticals Inc. will provide a corporate update and report its first-quarter 2024 financial results on May 13, 2024. The company, focused on dermatology therapeutics, will host a conference call and live webcast to discuss its financial performance and future prospects. Investors can participate via telephone or webcast to learn about Verrica's progress and financial status.
Summary not available.